In muscle, mutant genes can be targeted and corrected directly by intramuscular (i.m.) Recent studies have shown that systemic administration of wt (non-mdx) bone marrow (BM) cells to the tail vein of mdx mice leads to the segregation of some of the donor cells to the cardiac and skeletal muscles.
Recent studies have shown that systemic administration of wt (non-mdx) bone marrow (BM) cells to the tail vein of mdx mice leads to the segregation of some of the donor cells to the cardiac and skeletal muscles. 1, 2 The direct consequence of this is that normal dystrophin is expressed in the cells that end up in the muscle. With non-autologous wt cell transplantation in dystrophic muscle however, there is a significant possibility of donor cell rejection, leading to eventual graft failure. The potential development of autologous strategies for the remodeling of dystrophic muscle is therefore highly desirable in progressive muscle disorders. The supplementation of wt dystrophin by transplanted wt cells in mdx muscle provides good evidence that genetically corrected cells from a dystrophic individual may eventually be used to supplement dystrophic muscle with functional dystrophin.
Targeted gene correction has been applied to the dys locus of the mdx mouse using chimeraplasty 3 and by short fragment homologous replacement (SFHR) 4 ( Figure  1 ). Using both methods, targeted correction of the T to C nonsense transition has been achieved in 15 to 20% ( Figure 2b ) 4 and 15% 5 of cultured cells, respectively, but in very few cells (Ͻ1%) using in vivo applications. 3, 4 From this perspective, it seems that ex vivo correction, followed by injection of the corrected cells is the most likely mode by which to deliver genetically corrected loci to muscle. Further support for this strategy comes from the excellent frequencies of dystrophic muscle remodeling achieved by several groups using wt myoblast transplantation in the mdx mouse model of DMD over the past decade. 6, 7 Combined application of gene correction and cell transplantation means that cells from dystrophic individuals may be corrected ex vivo and applied as autologous therapeutic grafts to remodel their own muscle. Furthermore, successful remodeling of dystrophic muscle using muscle-derived 1 and BM-derived 1, 2 cells injected via the systemic (i.v.) route appears to occur with similar efficiency. This suggests that with further improvement, muscle remodeling may be achieved by systemic application of muscle and/or non-musclederived stem cells alike. In dystrophic muscle conditions such as DMD, the use of cells other than those derived from muscle is advantageous, because it gives access to renewable cell sources that are likely to be more abundant and accessible than muscle progenitors. Whilst the reason(s) for the low efficiency with which systemically (i.v.) injected cells remodel dystrophic muscle is unclear, it is possible that conditioning of donor cells by the tissue into which they are injected may play some determinant role. Thus it may be possible to influence the muscle-remodeling efficiency of injected non-muscle donor cells by mode of administration. In this study, the comparative effect of two systemic modes of BM injection (intraperitoneal and intravenous) on muscle remodeling is investigated.
lated and expanded, cell therapy seems presently the most favorable vehicle by which to deliver gene correction throughout muscle tissues. Using wt bone marrow as a model, this study investigates systemic application of bone marrow-derived cells as potential vehicles to deliver corrected (ie wt) dys locus to dystrophic muscle. Intravenous (i.v.) and intraperitoneal (i.p.) injections of wt BM were given to lethally and sub-lethally irradiated mdx mice. Despite both i.v. and surviving i.p. groups containing wt dys loci in
We injected four groups of (n = 5/group) C57BL10J mdx mice with 25 × 10 6 cells extracted from the bone marrow of C57BL10J wt mice. The four groups were first divided into two groups of 10 mice and irradiated with 12 Gy and 4 Gy of radiation, respectively, to impart differential lethality on recipient target tissue. Each group of 10 irradiated mice was then subdivided into two groups of five: one injected i.p., the other injected i.v. The injection protocol is fully outlined in Figure 1 .
After 2 weeks, all five of the lethally irradiated mice injected by the i.p. protocol had died, compared with no deaths in the remaining three groups, including the lethally irradiated, i.v. group. The death of the mice in this group indicated that i.p. injection was not as efficient in remodeling recipient bone marrow, presumably due to differences in the systemic passage of injected donor cells. Evaluation of dystrophin gene locus was performed on the peripheral blood (PB; eye bleeds) of surviving mdx recipients at 4 weeks, 3 months and 6 months after injection of wt cells to establish the status of bone marrow progenitors in the recipient animals. At 4 weeks, all animals in the lethally and sub-lethally irradiated i.v. injected groups displayed the presence of wt loci in 100% of PB cells. At this point, there was very little evidence of wt loci in the PB of the sub-lethally irradiated mice injected i.p. (Ͻ1%). This result further highlighted the different efficiency of recipient BM remodeling achieved by the two methods of injection. From these results, it was hypothesized that the differences in remodeling, caused by different paths of the cells may be accompanied by differences in the end-point localization of the introduced cells. Further, it was anticipated that with less 'remodeling activity' apparently getting to the bone marrow via the i.p. route, this remodeling activity might end up in tissues or tissue types encountered before the bone marrow cavity (eg diaphragm muscle, etc) of the i.v. route.
In PB, the relative proportions of wt and mdx dys loci were maintained throughout the 6 months after injection, at which point the recipient mdx mice were killed, and their blood and skeletal muscle (diaphragm and tibialis anterior (ta)) were assayed for wt dystrophin gene and wt dystrophin expression, respectively. At 6 months after injection, there appeared to be no quantitative differences observed in the proportion of dystrophin-positive fibers expressed within the two muscle groups analyzed. In comparing the relative proportions of dystrophin-positive fibers expressed in ta compared with diaphragm muscle, there was a significantly greater proportion of fibers apparently expressing wt dystrophin in the ta mus- 
Figure 2 Detection and quantification of wt dys loci amongst mdx dys loci. (a) Strategy for quantification of wt dys

was obtained by poly-t primed reverse transcription (Promega). After purification of primary PCR products using reverse phase chromatography (Qiagen), a second PCR was performed on 50 ng of the amplification product, using the MaeS-1 and Ex AS-1 primers as shown with the inclusion of ␣P
-dCTP radiolabel. The MaeS-1 primer is 3' end-modified to result in MaeIII restriction site acquisition in the presence of the wt nucleotide at the mdx dys locus. 4 In the absence of wt locus, the secondary PCR product (1 to 2 g) is cleaved overnight at 55°C into two fragments, 60 and 44 bp in length at an existing MaeIII site. In the presence of the wt nucleotide, the 44 bp fragment is further cleaved to give two fragments 20 and 24 bp long (Figure 1b, controls). These fragments are then resolved on a 20% acrylamide gel and visualized by phosphorimager screen exposure. (b) Quantification of wt loci generated by SFHR correction at the mdx dys locus. The presence of wt loci at the mdx locus was assayed in DNA extracted from mdx cell cultures subjected to mdx locus correction by SFHR. 4 Cultures were found to contain between 15 and 20% of wt loci after a double application of SFHR (2S) using Lipofectamine (Life Technologies, Rockville, MD, USA), and between 1 and 2% after a single application (1S) using Lipofectin reagent (Life Technologies). Incomplete digestion by the MaeIII enzyme is indicated by an asterisk ( * ). (c) Standard curve for wt dys locus quantification. DNA extracted from wt and mdx cell cultures was mixed to result in the wt dys proportions shown.
8 These mixtures were then subjected to the PCR-RFLP protocol outlined in (a) above, digested and run on an acrylamide gel. The absolute level of detection using this method was determined to be 1% wt loci. 8 cle of the sub-lethal/IP mdx group (Table 1 and Figure  3a) . This result did not support the earlier hypothesis that a different route of systemic administration may lead to a different effect on the extent to which the donor wt cells would remodel the dystrophic mdx muscle via the systemic route. Furthermore, the results of the dystrophin protein immunohistochemistry, and the results of the PB dys locus analysis collectively suggested that the extent Table 1 Analysis of wt dys locus and mRNA in mdx mice systemically injected with wt BM of muscle remodeling by wt donor BM was not related to the extent to which the donor BM cells repopulated the hemopoietic system. The latter observation was further investigated by analysis of dys transcripts in the ta muscle of recipient mdx mice. Using a PCR-RFLP technique to differentiate wt and mdx dys transcripts, 8 it was found that all groups expressed wt dys loci in the ta to equivalent extent (Figure 3b ), each at around the limit of the method's level of resolution (approximately 1% of transcripts). These levels of mdx muscle remodeling by wt BM cells fall within the general range identified in similar experiments by others using i.v. administration.
1,2 Whilst immunohistochemical staining for dystrophin indicated apparently elevated expression of wt dystrophin in the recipient mdx muscle, the protein levels did not correspond to levels of wt dys transcript present in the tissues. This discrepancy may arise from expansion of wt dystrophin protein in fibers with a selectional advantage over fibers expressing mutant dystrophin protein. Alternatively, whilst dystrophin-positive fibers observed in recipient mdx mice generally differed from those of agematched non-transplant mdx mice (f = 0.9%, data not shown), the resolution of true wt fibers from revertant mdx fibers using this dystrophin antibody remains to be clarified here.
The absence of any obvious relationship between extent of mdx mouse recipients' BM and muscle remodeling by systemically injected wt donor BMderived cells suggests that the muscle-remodeling activity of cells in the BM does not reside in the hemopoietic compartment responsible for recipient BM reconstitution. This is consistent with late preplate myogenic cell populations' ('PP6') lacking expression of the CD45 hemopoietic lineage cell surface antigenic determinant. 9 Myogenic cells introduced through the i.v. route are significantly less efficient at recipient muscle remodeling than when they are introduced by direct i.m. injection into dystrophic muscle. 1, 9 The discrepancy in ability of systemically injected myogenic cells to remodel dystrophic muscle may give some insight into the relevance of BM cells to remodel dystrophic muscle. Levels of dystrophic muscle remodeling attained by systemically introduced BM cells reported here and by others, are similar to those obtained by i.v. injected myogenic cells. With myogenic cells, the remodeling efficiency obtained by direct injection into skeletal muscles is significantly better than that obtained by i.v. injection. Whilst the mechanism(s) underlying this discrepancy remain unclear for the time being, one possibility is that the application of the cells directly into the muscle imposes a 'muscle-specific' environmental influences on the injected cells, thereby promoting their muscle remodeling capacity. Indirect support for this possibility exists in the improvement in muscle remodeling capacity induced by co-administration of the myotrophic cytokine LIF. [10] [11] [12] Alternative reasons include the possibility that systemic injection allows only a small proportion of cells to reach the muscle compared with when cells are injected into the intramuscular (i.m.) route.
The data presented in this communication establish that no differences are observed with regard to the muscle remodeling capacity of systemically injected BM cells administered by i.p. or i.v. routes. Further, the data presented here suggest that the myogenic remodeling capacity observed in BM-derived cells is not related to the BM reconstituting capacity, and therefore unlikely to be related to hemopoietic cells in the BM. Further study of the factors responsible for BM-derived cells' commitment to muscle lineage are needed to establish the viability of BM cells for dystrophic muscle remodeling. If muscle remodeling-capable BM-derived stem cells can be effectively isolated, applied gene correction strategies such as SFHR and chimeraplasty will open an avenue towards the autologous remodeling of dystrophic muscle in neuromuscular disorders, such as DMD.
